GMP-Creative Biolabs provides one-stop customer-oriented services including biopharmaceutical contract R&D, process development, cGMP manufacturing, QA & QC solutions for scientific research, preclinical, clinical and commercial supply. We proceed your projects according to your specific demands in quality, timeline and budget, supporting researchers across different therapeutic areas. Clear, open and regular communication with customers is as important to our success as our in-depth scientific knowledge. more
Creative Biolabs provides full services of recombinant NS0 cells for recombinant proteins production. It has been a number of years that NS0 cells work as fusion partners for the generation of hybridoma cells to produce monoclonal antibodies. And recent years, NS0 cells are also an important host cells for recombinant proteins production in their own right. There have been several monoclonal antibodies that are produced by NS0 and approved by FDA or/and EMA.
The starting point for developing NS0 cell line can be traced to the discovery that injection of mineral oil into mice could induce plasma-cell neoplasms. NS0 cell line originated from the isolated cells of MOPC21 plasmacytoma tumor which was found to secrete IgG1. After generation of clones, the cell line that did not secrete or synthesize heavy or light chains of Ig was generated and hence it was called NS0/1 (non-secreting). In short, the historical development of the NS0 cell line can be summarized as MOPC21 plasmacytoma tumor-isolated cells cultured in vitro and frozen-cells revived, 9 serial transplantations in mice, cells cultured in vitro-P3K cells-P3/X27-289/16-NSI/1-P3/NSI/1/Ag4/1-NS0. Like most types of myeloma cells, NS0 cells have been used for many years as efficient fusion partners to product hybridoma cells producing monoclonal antibodies. And in recent years, NS0 has become an important host cell for recombinant proteins production especially combination with GS selection system. There have been at least 6 antibodies that are manufactured using NS0 cell line: Daclizumab; Gemtuzumab; Natalizumab; Ofatumumab; Ozogamicin; Palivizumab.
GS system and antibiotic resistance are the two primary methods used in NS0 cell lines. NS0 cells are naturally deficient of glutamine synthetase (GS), containing extremely low levels of endogenous GS activity, which makes it straightforward to select in the absence of methionine sulphoximine (MSX). Moreover, in GS system, only a single round of amplification is sufficient to reach efficient levels of recombinant protein expression, which usually takes about 3 months. GS system is regarded as a high yielding system to produce recombinant proteins rapidly.
Scientist from Creative Biolabs will definitely accelerate your work in stable cell line development for research or industry use.
Creative Biolabs is capable of providing the following stable cell lines for various proteins expression:
To discuss your NS0 Cell Lines demands or to request a proposal, please contact us by
For R&D use only, not directly for clinical use.